The demand for Anti-Diabetes Drugs in Burkina Faso has been steadily increasing in recent years.
Customer preferences: Burkina Faso has a high prevalence rate of diabetes due to factors such as poor diet, sedentary lifestyles, and genetic predisposition. As a result, there is a growing demand for Anti-Diabetes Drugs in the country. Patients in Burkina Faso tend to prefer affordable and easily accessible drugs that are effective in managing their condition.
Trends in the market: The Anti-Diabetes Drugs market in Burkina Faso has been growing steadily due to the increasing prevalence of diabetes in the country. The market is dominated by multinational pharmaceutical companies that offer a range of drugs to manage diabetes. However, there is also a growing market for traditional medicines that are believed to be effective in managing diabetes.
Local special circumstances: Burkina Faso is a low-income country with limited healthcare infrastructure. This has led to challenges in the distribution and availability of Anti-Diabetes Drugs in the country. The government has implemented policies to improve access to healthcare, including the distribution of free anti-diabetes drugs to patients in public hospitals. However, the availability of drugs in rural areas remains a challenge.
Underlying macroeconomic factors: Burkina Faso has a growing economy, but it is still one of the poorest countries in the world. The country relies heavily on agriculture, which is vulnerable to climate change and other external factors. This has implications for the availability and affordability of Anti-Diabetes Drugs in the country. The government has implemented policies to encourage investment in the healthcare sector, but more needs to be done to address the growing demand for Anti-Diabetes Drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
